New legal powers and pilot projects could give South Korean health authorities a faster way to identify suspected vaccine side effects and connect higher-risk patients with clinicians.
South Korea is moving to tighten oversight of vaccine side effects by pairing new legal powers with artificial intelligence tools that can flag possible adverse reactions sooner and connect patients with clinicians for follow-up.
According to eToday, a recent case in which an AI system classified a vaccinated person’s symptoms as a higher-risk adverse reaction and sent the information to medical staff for a remote consultation suggests the technology may already be usable in real clinical settings. The report said the system analysed the timing, severity and type of symptoms, as well as underlying conditions, before sorting the case into a management category and prompting a clinician review.
The development comes as lawmakers have approved a bill on immunisation management that would create a stronger statutory basis for reporting and handling side effects after vaccination. The legislation is intended to support an integrated national system that can collect reports even when a causal link to a vaccine has not yet been confirmed, helping authorities spot early safety signals more quickly. That approach echoes earlier efforts in South Korea to build more active vaccine surveillance after the Covid-19 rollout, including the launch of a vaccine safety committee and calls from experts for nationwide data sharing and clearer criteria for judging causality.
The technology has also been tested in the field. The Korea Association of Health Promotion’s Gangwon branch ran a pilot project that checked recipients’ condition at set intervals after vaccination and used AI to sort possible side effects by risk level. When the system identified a potentially serious case, it alerted medical staff and linked the person to a non-face-to-face consultation. Because the association operates branches across the country, the trial has raised the prospect of broader use if the results are judged effective.
A crucial question now is whether the system can move from pilot projects to routine practice. The Health Insurance Review and Assessment Service is working on guidelines for evaluating AI medical technologies for formal reimbursement, a step that could determine how widely such tools are adopted. Industry figures cited by eToday say AI-based monitoring is not only about detecting side effects, but also about directing care towards people most likely to need it, making it potentially useful for local governments and public health centres that oversee post-vaccination follow-up.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
